JP Morgan Healthcare, Day 3: Puma Biotechnology, Natera | Precision Oncology News
Puma Biotechnology
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
A Top Puma Bio Exec Resigns Ahead of FDA Panel, Analysts Defend With Conflicting Stories - TheStreet
Puma Biotech to pay PPD founder $22M in defamation suit from proxy fight | Fierce Pharma
Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
Is Puma Biotechnology Inc. late reporting EU clinical trials?
Puma Biotechnology | Evaluate
Puma Biotechnology: Finding Bullish Indications At The End Of 2019 (NASDAQ:PBYI) | Seeking Alpha
Efficacy of neratinib in hormone receptor-positive patients who initiated treatment within 1 year of completing trastuzumab- bas
Puma Biotechnology Announces $10 Million Private Placement | Business Wire
Puma Biotechnology, Pierre Fabre enter into license agreement to develop and commercialize NERLYNX in Europe - Pharmaceutical Business review
Puma Biotechnology breast cancer drug approved in EU | S&P Global Market Intelligence
Puma Biotechnology
Puma Biotechnology, Inc. 2020 Current Report 8-K
With EU Approval For Puma Biotech's Breast Cancer Drug Unlikely, Cowen Downgrades
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology
Puma Biotechnology
Puma Biotechnology
Puma Biotechnology obtains dismissal of opposition against its European patent relating to treatment for gefitinib/erlotinib-resistant cancers and cancers with T790M EGFR mutation | Experience | Jones Day
Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT 'Basket' Trial of Neratinib at the ASCO 2022 Annual Meeting | Business Wire
European Commission Grants Marketing Authorisation for Puma Biotechnology's NERLYNX® (neratinib) for Extended Adjuvant Treatm
Puma Biotech gets EU panel nod for breast cancer drug, Health News, ET HealthWorld
Puma Biotechnology Announces $10 Million Private Placement | Business Wire
